A recent single-cell transcriptome analysis on SHH medulloblastoma showed that cell diversity confers resistance to targeted therapy.43 Moreover, Petrirena et al. reported a patient with a PTCH1 mutated medulloblastoma who developed under vismodegib 2 different SMO mutations in 2 different metastatic sites at different allelic fraction.42 Here, SMO is linked to medulloblastoma.